Aarti Pharmalabs Limited has informed the stock exchanges that the Board of Directors meeting, originally scheduled for Monday, May 18, 2026, has been postponed and rescheduled to Monday, May 25, 2026. The postponement intimation was issued on May 14, 2026, in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, referencing the earlier intimation dated May 11, 2026.

Revised Board Meeting Details

The rescheduled Board meeting will address the same agenda items as originally planned. The following table summarises the updated meeting details:

Financial Results and Dividend Consideration

The Board will consider and approve the audited financial results of the company for the quarter and financial year ended March 31, 2026, after these results are reviewed by the Audit Committee of the Board. Additionally, the Board will deliberate on whether to recommend a final dividend for the financial year ended March 31, 2026, subject to applicable approvals.

Trading Window Closure

In accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in the securities of Aarti Pharmalabs had been closed from April 01, 2026. Following the postponement of the Board meeting, the Trading Window shall now remain closed until 48 hours after the declaration of the financial results, i.e., till May 27, 2026.

The postponement intimation was signed by Jeevan Mondkar, Company Secretary and Legal Head (ICSI M. No. A22565), on behalf of Aarti Pharmalabs Limited.

Aarti Pharmalabs Limited has submitted its quarterly compliance certificate under SEBI regulations for the fourth quarter of fiscal year 2026, marking another routine regulatory filing by the pharmaceutical company.

Regulatory Compliance Filing

On April 07, 2026, aarti pharma labs filed its certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The filing was made simultaneously to both major stock exchanges where the company's shares are listed.

Certificate Details and Confirmation

The compliance certificate was issued by MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, which serves as the company's Registrar and Share Transfer Agent. The certificate confirms adherence to SEBI's depositories and participants regulations for the specified quarter.

According to the documentation, MUFG Intime confirmed that securities received from depository participants for dematerialisation during Q4 FY26 were properly processed and confirmed to the depositories within prescribed timelines. The registrar also verified that security certificates received were appropriately mutilated and cancelled after due verification.

Key Compliance Highlights

The certificate reveals several important compliance aspects:

• No dematerialisation requests were received from shareholders during the quarter ended March 31, 2026
• The certificate was issued specifically for compliance purposes at the company's request
• All regulatory procedures for handling securities and maintaining member registers were followed as per SEBI guidelines
• Prescribed timelines for processing and confirmation were maintained throughout the quarter

Corporate Governance Framework

The filing was executed by Jeevan Bhargav Mondkar, who serves as Company Secretary and Legal Head with ICSI membership number A22565. The document was digitally signed on April 07, 2026, demonstrating the company's adoption of digital compliance processes.

MUFG Intime India Private Limited, with CIN U67190MH1999PTC118368, operates from its registered address in Vikhroli, Mumbai, and continues to provide registrar services to Aarti Pharmalabs Limited from its Vapi, Gujarat operations.

Regulatory Significance

This quarterly filing represents part of the ongoing regulatory compliance framework that listed companies must maintain under SEBI regulations. The certificate ensures transparency in the handling of securities and maintains investor confidence through proper documentation of depositories and participants' activities during the reporting period.